Leukaemic stem cells

Transfus Med. 2003 Dec;13(6):363-75. doi: 10.1111/j.1365-3148.2003.00464.x.

Abstract

All haemopoietic cell lineages arise from multipotential self-renewing stem cells that give rise to committed progenitor cells. These progenitor cells subsequently differentiate into more lineage-committed cells with a restricted range of plasticity. A hierarchical order is considered to exist, where lineage commitment and differentiation are thought to be irreversible. As cells differentiate, they gradually lose the ability to self-renew. The most primitive haemopoietic progenitor cells have the ability to reconstitute long-term haemopoiesis in myeloablated recipients. However, as cells differentiate, there is an orchestrated silencing of some genes and activation of others, resulting in lineage commitment and generally a reduction in proliferative ability. Here, we discuss potential differences between normal and leukaemic stem cells, some of which may have therapeutic implications.

Publication types

  • Review

MeSH terms

  • Animals
  • Antigens, CD34 / analysis
  • Antineoplastic Agents / pharmacology
  • Cell Line, Tumor / cytology
  • Cell Transformation, Neoplastic / genetics
  • Cell Transformation, Neoplastic / pathology
  • Dogs / embryology
  • Drug Design
  • Hematopoietic Stem Cells / cytology
  • Humans
  • Leukemia / drug therapy
  • Leukemia / genetics
  • Leukemia / pathology*
  • Mice
  • Mice, Inbred NOD
  • Mice, SCID
  • Neoplastic Stem Cells / cytology*
  • Oncogene Proteins, Fusion / genetics
  • Oncogene Proteins, Fusion / physiology
  • Sheep / embryology
  • Translocation, Genetic
  • Tumor Stem Cell Assay
  • Xenograft Model Antitumor Assays

Substances

  • Antigens, CD34
  • Antineoplastic Agents
  • Oncogene Proteins, Fusion